CagriSema Reference Overview

Compound Reference Overview

Mechanism of Action (Educational)

CagriSema is an investigational fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist).

Cagrilintide activates amylin receptors in central appetite-regulating regions, contributing to increased satiety, reduced caloric intake, delayed gastric emptying, and suppression of postprandial glucagon secretion.

Semaglutide activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and modulating appetite through central and peripheral pathways.

The combination is being studied to evaluate whether complementary satiety signaling through both amylin and GLP-1 pathways results in greater weight reduction and metabolic effects compared with monotherapy. All outcomes remain trial-dependent.

Indications (Investigational)

• Obesity (Phase 3 clinical development)
• Type 2 diabetes mellitus (clinical development)
• Cardiometabolic risk modification (investigational)

Administration (Clinical Development Reference)

Pharmacokinetics (Clinical Development)

Both components demonstrate pharmacokinetic profiles compatible with once-weekly dosing. Semaglutide has a half-life of approximately ~7 days, while cagrilintide demonstrates a prolonged duration of action consistent with weekly administration.

Steady-state concentrations are typically achieved after several weeks of therapy. Metabolism occurs through peptide degradation pathways.

Titration Schedule (Clinical Development Reference)

The following escalation reflects paired-dose sequences evaluated in investigational programs and is provided for literature reference only.

• Weeks 1–4: 0.25 mg / 0.25 mg once weekly
• Weeks 5–8: 0.5 mg / 0.5 mg once weekly
• Weeks 9–12: 1.0 mg / 1.0 mg once weekly
• Weeks 13–16: 1.7 mg / 1.7 mg once weekly
• Week 17+: 2.4 mg / 2.4 mg once weekly

Gradual escalation is used to improve gastrointestinal tolerability. Slower titration may reduce nausea and vomiting.

Reconstitution & Concentration
(Mathematical Standardization Model)

For educational standardization purposes, concentration may be normalized so that 0.10 mL (10 insulin units) = 0.25 mg / 0.25 mg. This supports clean paired titration increments.

Conversion Reference (Paired Doses)

• 10 units = 0.25 mg / 0.25 mg
• 20 units = 0.5 mg / 0.5 mg
• 40 units = 1.0 mg / 1.0 mg
• 68 units = 1.7 mg / 1.7 mg
• 96 units = 2.4 mg / 2.4 mg

This section is provided strictly for arithmetic illustration and does not constitute dosing guidance. Investigational products may have different preparation requirements.

Safety & Contraindications (Summary)

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Known hypersensitivity to either component
• Pregnancy or breastfeeding

Relative Cautions

• Severe gastrointestinal motility disorders (e.g., gastroparesis)
• History of pancreatitis
• Concomitant insulin or sulfonylurea therapy

Adverse Events

• Nausea (dose-dependent)
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite

Serious Adverse Events

• Pancreatitis
• Gallbladder disease
• Severe gastrointestinal intolerance

Drug Interactions

• Insulin or sulfonylureas may increase hypoglycemia risk
• Delayed gastric emptying may alter absorption of oral medications

Monitoring (Clinical Development Reference)

• Blood glucose levels
• Body weight and appetite changes
• Renal function (if significant vomiting or dehydration occurs)
• Signs or symptoms of pancreatitis
• Gastrointestinal tolerability during escalation

Mathematical Calculation Tool

The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes.
This tool is provided strictly for arithmetic reference.

Disclaimer

CagriSema is an investigational combination and is not FDA approved. This content is provided strictly as a pharmacologic and mathematical reference for educational and professional purposes. It does not constitute medical advice, prescribing guidance, diagnosis, or treatment recommendations. All clinical decisions must be made by a licensed healthcare professional in accordance with applicable regulations.

Reference Sources